Recently, Moderna (NASDAQ: MRNA)'s CEO highlighted a big risk for the company: Demand for its COVID-19 vaccine is going to crater. It's a big enough decline to get investors worried. Moderna is anticipating a big drop in demand this year as concerns around COVID-19 subside.